Valencia, Spain, April 14, 2026 –— Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced its participation in the 25th Annual Needham Virtual Healthcare Conference, taking place April 13-16, 2026.
Company management will meet with investors in one-on-one meetings during the conference.
About ARTHEx Biotech
ARTHEx Biotech is a clinical-stage company developing targeted RNA medicines designed to precisely modulate gene expression. Its proprietary platform, BOOST-ON™, pairs selective oligonucleotides with enhanced tissue delivery to reach skeletal muscle, heart, and brain. Its lead program, ATX-01, is in clinical evaluation for myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS and cardiac diseases.
The Company headquarters are in Valencia, Spain.
For more information on ArthemiR™, please visit https://www.arthemir.com or https://clintrials.gov. For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.
Company Contact
Frédéric Legros
Executive Chairman and CEO
flegros@arthexbiotech.com
+33679495790
Investor and Media Contact
Amy Conrad
Juniper Point
amy@juniper-point.com
+1 858-366-3243
